| COPENHAGEN, Denmark, Nov. 2, 2011 (GLOBE NEWSWIRE) -- Interim Report for the 9 Months Ended September 30, 2011 Guidance for continuing operations improved due to reduction in expenses Fair value of our manufacturing facility reduced by DKK 342 million and expected sale moved into 2012; guidance updated with new projected cash position Arzerra(R) net sales increased by 45% over prior year nine month period Positive top-line Phase II data from study of ofatumumab in second line ag...continued GNMSF GNMSY |
Wednesday, November 2, 2011
Genmab Announces Financial Results for the First Nine Months of 2011 and Updated 2011 Financial Guidance
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment